Summary of IPI-145 Data in Advanced Hematologic Malignancies Presented at ICMLIn total, the Phase 1 data of IPI-145 reported in three separate presentations at ICML included patients with B-cell lymphoma (51 patients evaluable for safety and 38 for response), CLL (34 patients evaluable for safety and 22 for response) and T-cell lymphoma (17 patients evaluable for safety and nine for response). 2,3,4 These patients had advanced disease and had progressed during or were refractory to, intolerant of, or ineligible for established therapy. Patients had a median of four prior systemic therapies (range: 1 to 13), and 69 percent of patients had at least three prior systemic therapies.
Infinity Reports Phase 1 Data Showing Encouraging Clinical Activity Of IPI-145 Across A Broad Range Of Blood Cancers At The 12th International Conference On Malignant Lymphoma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts